Digest Network Come funziona
Network
/
Società
In
Non verificato

Incyte

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

105 comunicati stampa

Guarda tutti i comunicati
08/06/2026
Web e Social Network
Mercato azionario
Telefonia e Varie
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
Fonte
Incyte
Emittente
Business Wire
1.00
0
30/05/2026
Oncologia
Salute
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
Eventi
Industria
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
Fonte
Incyte
Emittente
Business Wire
1.00
0
26/05/2026
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Web e Social Network
Eventi
Industria
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Fonte
Incyte
Emittente
Business Wire
1.00
0
12/05/2026
Eventi
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
Fonte
Incyte
Emittente
Business Wire
1.00
0
01/05/2026
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
Fonte
Incyte
Emittente
Business Wire
1.00
0
29/04/2026
Eventi
Web e Social Network
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Incyte to Present at Upcoming Investor Conferences
Fonte
Incyte
Emittente
Business Wire
1.00
0
28/04/2026
Mercato del lavoro
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer
Fonte
Incyte
Emittente
Business Wire
1.00
0
28/04/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Oncologia
Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates
Fonte
Incyte
Emittente
Business Wire
1.00
0
21/04/2026
Eventi
Fiere
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Fonte
Incyte
Emittente
Business Wire
1.00
0
09/04/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Oncologia
Incyte to Report First Quarter Financial Results
Fonte
Incyte
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0